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Breathing difficulties in sleep are a hallmark of sleep-disordered breathing commonly observed in patients with sleep disorders.The
pathophysiology of sleep apnea is in part due to an augmented activity of the carotid body chemoreflex. Arterial chemoreceptors in
the carotid body are sensitive to inflammatory cytokines and immunogenicmolecules in the circulation, because cytokine receptors
are expressed in the carotid body in experimental animals and human. Intriguingly, proinflammatory cytokines are also locally
produced and released in the carotid body. Also, there are significant increases in the expression of proinflammatory cytokines,
cytokine receptors, and inflammatory mediators in the carotid body under hypoxic conditions, suggesting an inflammatory
response of the carotid body. These upregulated cytokine signaling pathways could enhance the carotid chemoreceptor activity,
leading to an overactivity of the chemoreflex adversely effecting breathing instability and autonomic imbalance. This review aims
to summarize findings of the literature relevant to inflammation in the carotid body, with highlights on the pathophysiological
impact in sleep apnea. It is concluded that local inflammation in the carotid body plays a pathogenic role in sleep apnea, which
could potentially be a therapeutic target for the treatment of the pathophysiological consequence of sleep apnea.
1. Introduction
Sleep apnea is the most prevalent form of sleep-disordered
breathing, which is characterized by recurrent breathing
pauses lasting over 10 seconds due to a repeated narrow-
ing or closure of the upper airway and/or a periodic halt
of the central drive for respiratory activities during sleep.
Sleep apnea syndrome is closely associated with episodes of
desaturated arterial blood oxygen, sleep fragmentation, and
arousals in the patient. As a consequence of sleep apnea, it
causes excessive daytime sleepiness and increases the risk of
neurocognitive dysfunction and cardiovascular morbidities
in young and adult patients [1, 2]. The pathophysiology and
consequences of sleep apnea have been extensively studied
over decades. A growing amount of evidence suggests that the
carotid chemoreflex elicited by arterial chemoreceptors in the
carotid body in response to episodes of hypoxia (intermittent
hypoxia) in sleep apnea plays a role in the pathophysiological
cascade [3]. Specifically, there are significant increases in the
chemosensitivity and the activity of the carotid chemore-
ceptor induced by hypoxia in experimental animals and in
patients with sleep apnea [4, 5]. Thus, mechanisms underly-
ing the augmented activity of the carotid chemoreceptor are
currently a focus of investigation.
Arterial chemoreceptors in the carotid body play an
important physiological role in the chemotransduction of
chemical changes in the arterial blood, which is essential
to elicit the chemoreflex for rapid adjustment of respiratory
and cardiovascular activities to maintain blood gases and
pH homeostasis. Thus a lowered arterial oxygen or pH level
causes an increase in the chemoreceptor activity of the carotid
body [6]. The increased afferent activity via the carotid sinus
nerve projects to the nucleus tractus solitarius in themedulla,
through which the primary relaying neurons activate the
central pathway of the chemoreflex. This in turn increases
the central drive for ventilation and also alters cardiac and
autonomic activities for the compensatory changes adjusting
to metabolic needs [7].
The carotid body is bilaterally located at the bifurcation
of the carotid artery, which is structurally analogous to vagal
paraganglia. The major cell type in the carotid body is type-
I glomus cells, which are chemosensitive and responsive to
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chemical changes in the arterial blood. These cells form
lobular clusters and are apposed to afferent nerve endings,
which are essential for the sensory chemotransduction [6, 8].
These glomic clusters are encapsulated by type-II sustentac-
ular cells, which are glial like and are recently known to play
a role in the paracrine signaling in the chemotransduction
and other housekeeping functions [9]. In responding to
hypoxia, chemosensitive type-I glomus cells are depolarized
with an inhibition of potassium currents causing an elevated
level of intracellular calcium, which triggers the vesicular
release of neurotransmitters acetylcholine and ATP as well as
neuromodulators including catecholamines and neuropep-
tides from the chemosensitive cells [10]. This elevates the
excitability of the nerve endings which increases the activity
of the carotid sinus nerve of the carotid body for eliciting the
chemoreflex.
The carotid body is highly vascularized with blood
perfusion from the carotid artery far more than the local
metabolism [6]. Thus, the chemosensory component of the
carotid body is in a close diffusion distance responding to
any changes in arterial oxygen tension or pH, circulating
hormones or signaling molecules, and also substances locally
produced by vascular cells and tissues acting as autocrines or
paracrines. For example, signaling molecules in the arterial
blood and locally produced in the carotid body including
vasoactive peptides endothelin-1, angiotensin II, and also
proinflammatory cytokines have been shown tomodulate the
excitability of the carotid chemoreceptor [11, 12]. Also, the
cytokine receptors are functionally expressed in the carotid
body [13–15]. These findings provide initial evidence for a
role of cytokine signaling in the carotid body, which raises a
number of questions on the following: (i) the physiological
significance of the expression of cytokines and cytokine
receptors in the carotid body, (ii) the regulation of the cy-
tokine signaling pathway in the carotid body under physio-
logical or pathophysiological conditions, and (iii) alterations
of the carotid chemoreceptor activity by cytokines and the
pathophysiological significance of carotid body inflammation
in disease conditions.
2. The Carotid Body Is a Peripheral Sensor of
Inflammatory Cytokines
Both the central and peripheral nervous systems play roles
in the communication between the brain and the immune
system, which is important for the regulation of immune
and brain responses to inflammation under physiological or
disease conditions. The circumventricular organs are impor-
tant structures where central neurons respond to cytokines
in the blood, whereas the visceral activity of the vagus nerve
is crucial to the afferent projection of immunogenic signals
to the central [16]. In addition, recent studies suggest a
role of the peripheral chemoreceptor in the carotid body
in the immunosensing of inflammatory cytokines, by which
the elicitation of the activity of the chemoreflex pathway
could be an important part of the ventilatory response and
altered cardiovascular and autonomic activities adjusting to
the inflammatory status.
It is well known that the biosynthesis and release of
inflammatory cytokines, including interleukin- (IL-) l𝛽 and
IL-6 and tumor necrosis factor- (TNF-) 𝛼 in the immune
cells play important roles in the peripheral mediation of the
physiological and pathophysiological changes under inflam-
matory and/or infective conditions. In experimental animals,
it has been reported that IL-1 type-1 receptors are expressed in
glomus cells of vagal paraganglia [17]. Also, the IL-1 receptors
are expressed in the type-I glomus cells of the carotid body,
suggesting an immunosensory function of the carotid body
[13, 15, 18]. Functionally, extracellular application of IL-1𝛽
significantly decreases the outward potassium current in cul-
tured glomus cells of the carotid body [19]. In addition, topical
application of IL-1𝛽 to the carotid body increases the activity
of the carotid sinus nerve in rats [19]. Also, exogenous IL-1𝛽
induces an elevated level of intracellular calcium response to
hypoxia in the glomus cell of the carotid body [15]. Besides
the expression of IL-1 receptors, components of the IL-6
receptor, namely, IL-6 receptor alpha chain and gp130, are
expressed in the type-I glomus cell and possibly in type-II and
vascular cells of the rat carotid body (Table 1).These receptors
are functional because exogenous application of IL-6 to the
glomus cells increases the intracellular calcium response to
hypoxia [15]. These observations support a role of the carotid
body in sensing proinflammatory cytokines via the cytokine
receptors.
In addition to proinflammatory cytokines IL-1𝛽 and IL-
6, Ferna´ndez et al. [20] reported that infusion of lipopolysac-
charide (LPS) increases respiratory rate in the cat, which is
abolished by sectioning the carotid and aortic nerves. The
carotid chemoreceptor activity is also increased by the intra-
venous LPS administration [20]. The carotid chemoreceptor
response to LPS could be mediated by toll-like receptor 4,
which is the LPS canonical receptor, expressed in the carotid
body. Also, LPS induces the release of TNF-𝛼 from immune
cells [21, 22]. It raises the possibility that the effect of LPSmay
be mediated by TNF-𝛼. Indeed, the TNF receptors, namely,
TNF-r1 and TNF-r2, are expressed, respectively, in the type-
I glomus cell and endothelial cell of the cat carotid body
[20]. In the rat, the TNF receptors are also expressed in the
type-I glomus cell and possibly type-II and vascular cells of
the carotid body (Table 1). Exogenous application of TNF-
𝛼 to the rat glomus cell increases the intracellular calcium
response to hypoxia [15]. However, TNF-𝛼 attenuates the
carotid chemosensory response to hypoxia in the cat [20].
Nevertheless, these findings support a role of the glomus cells
in sensing and transmitting immune signals by responding
to the proinflammatory cytokines via their corresponding
receptors.
In human, inflammation of the carotid body has been
reported to be related to aging or autoimmunity disease.
The histological feature of carotid glomitis is associated with
follicles of lymphocytes and also infiltration of immune cells
with morphological changes in the type-I and type-II cells in
the carotid body [23]. More recently, cytokine receptors for
IL-1𝛽, IL-6, IL-10, and TNF-𝛼 as well as toll-like receptors
are also found to be expressed in the human carotid body
[24, 25]. These findings are consistent with the findings in
Mediators of Inflammation 3
Table 1: A summary of main findings in literatures reporting the expression of cytokines and cytokine receptors in the carotid body of
rodents, cats, and humans; also changes in the expression level under hypoxic conditions, namely, sustained hypoxia (SH) or intermittent
hypoxia (IH) are shown.
Rat Mouse Cat Human SH IH
IL-1𝛽
IHC, PCR
[15, 18, 29, 30, 52,
62]
IA
[24]
+
[15, 29]
+
[18, 30, 52, 62]
IL-1r1 IHC, PCR, WB[13, 15, 18]
MA, IHC
[24, 25]
+
[15]
+
[18]
IL-4 IA[24]
IL-6 IHC, PCR[15, 18, 29, 30]
MA, IA
[24, 25]
+
[15, 29]
+
[18]
IL-6R𝛼 WB[14]
MA
[25]
MA, IHC
[24, 25]
gp130 IHC, WB[14, 15, 18]
MA
[25]
IL-8 IA[24]
IL-10 IA[24]
IL-10R MA[25]
TNF-𝛼
IHC, PCR, WB
[15, 18, 28–
30, 52, 62]
IHC, PCR
[20]
MA, IHC
[24, 25]
+
[15, 29]
+
[18, 30, 52, 62]
TNF-r1 IHC, PCR, WB[15, 18, 28]
MA
[25]
IHC, PCR
[20]
MA
[25]
+
[15]
+
[18]
TNF-r2 IHC, PCR, WB[28]
MA
[25]
IHC, PCR
[20]
MA
[25]
Techniques involved in the study—IA, immunoassay; IHC, immunohistochemistry; MA, microarray; PCR, polymerase chain reaction; WB, western blot; +,
increased expression.
experimental animals, suggesting an immunosensing func-
tion of the carotid body in its response to proinflammatory
cytokines and also other immunogenic molecules via the
corresponding receptors expressed in chemosensitive type-I
glomus cells and also other cell types in the organ.
3. Regulation of the Expression of
Proinflammatory Cytokines and Cytokine
Receptors in the Carotid Body
The carotid body and its chemoafferent activity could play
a role in the communication between the immune system
and the brain, in particular, in the inflammatory and infective
status [26]. It raises the possibility that the cytokine signaling
pathway in the carotid body may also be regulated by the
inflammatory cytokines and immunogenic molecules in the
circulation. Indeed, it has been shown that intraperitoneal
injection of IL-1𝛽 increases the expression of IL-1 type-I
receptors in the carotid body of the rat [27]. In addition,
infusion of LPS increases the expression of TNF-r2 receptor
in the rat carotid body [28]. These observations suggest
that the cytokine receptors in the carotid body are regu-
lated by inflammatory cytokines, which could modulate the
chemosensory activity and its response to proinflammatory
cytokines or hypoxia under inflammatory or disease condi-
tions.
Besides the circulating source of cytokines, a growing
amount of evidence supports that there is a local expression
of proinflammatory cytokines in the carotid body under
physiological or disease conditions. Ferna´ndez et al. [20]
reported the expression of TNF-𝛼 is particularly significant
following intravenous injection of LPS to induce endotox-
emia in the cat and the expression is colocalized to the type-I
and endothelial cells in the carotid body. This study provides
evidence suggesting that the TNF signaling pathway in the
carotid body, via activation of the chemoreflex, could be
functionally important in the ventilatory and cardiovascular
response to sepsis [26]. In the rat, the expression of TNF𝛼 has
also been shown in the carotid body under physiological and
hypoxic conditions (Table 1). In addition, proinflammatory
cytokines IL-1𝛽 and IL-6 are expressed in type-I glomus
cells (Table 1) and also in type-II cells of the carotid body
[29, 30]. Furthermore, cytokines IL-1𝛽, IL-4, IL-6, IL-8, and
IL-10 are reported to be released from carotid bodies in
patients with head and neck neoplasms [24]. Importantly, the
release of the cytokines is increased following a prolonged
period of hypoxia for an hour [24]. These findings suggest
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that cytokines locally produced in the carotid body are an
active component of the cytokine signaling pathway which
modulates the activity of chemoreceptors under physiological
or hypoxic conditions.
4. Sustained Hypoxia Induces Local
Inflammation in the Carotid Body
Inflammation plays an important role in physiological pro-
cesses, for instance, wound healing, and also a common
clinical condition manifested in a chronic manner in dis-
eases. In addition to infection and inflammation, evidence
suggests that the cytokine signaling pathway in the carotid
body is regulated by hypoxic conditions. In the circulation,
plasma levels of cytokines are elevated in altitude natives
and subjects sojourning at high altitude under a sustained
hypoxic condition [31–33]. Also, chronic inflammation is one
of the important clinical manifestations in patients with dis-
eases associated with chronic hypoxemia, including chronic
obstructive pulmonary disease [34, 35]. In fact, hypoxia and
inflammation are interrelated and the inflammatory response
to hypoxia can be adaptive or pathogenic in nature [36].
It is well known that inflammatory cytokines induced the
expression of nuclear factor kappa B- (NF𝜅B-) dependent
genes encoding inflammatory mediators including cyclooxy-
genases and inducible nitric oxide synthase (iNOS), which
could in turn modulate the expression of cytokines and
chemokines. In this regard, the expression of cytokines and
cytokine receptors in the carotid body may play roles in the
physiological acclimatization to altitude, particularly in the
modulation of carotid chemoreceptor activity, and also in
the pathogenic cascade in disease conditions associated with
chronic hypoxemia and inflammation.
We andothers have shown that hypoxia induces increased
expressions of proinflammatory cytokines IL-1𝛽, IL-6, and
TNF-𝛼 and the corresponding IL-1𝛽 receptor (IL-1r1), IL-6
receptor (gp130), and TNF receptor (TNF-r1) in the carotid
body of rats exposed to sustained hypoxia for days up
to 4 weeks [15, 29]. The upregulated expression of proin-
flammatory cytokines and cytokine receptors is localized to
the type-I glomus cell and is also expressed in the type-
II cell and immune cells in the carotid body in sustained
hypoxia [15, 29]. Importantly studies show that exogenous
cytokines induce an enhanced intracellular calcium response
to hypoxia in the glomus cell of rats exposed to sus-
tained hypoxia, suggesting that the upregulated expression
of proinflammatory cytokines and cytokine receptors plays
a functional role in the chemosensory function [15]. Also,
the enhanced carotid chemoreceptor activity induced by
sustained hypoxia is significantly blocked by a concurrent
treatment of the animal with an anti-inflammatory drug
ibuprofen or dexamethasone [29]. Furthermore, ibuprofen
prevents the increase in the ventilatory response to hypoxia
in rats exposed to sustained hypoxia [37]. These findings
strongly supported the notion that the activity of chemosen-
sitive glomus cells is enhanced by the locally produced
proinflammatory cytokines, mediated by the cytokine recep-
tors in a paracrine-autocrine signaling manner. In effect,
the cytokine signaling pathway plays a more prominent
role in the enhanced chemosensory activity under hypoxic
conditions with an upregulation of the local expression of
proinflammatory cytokines and cytokine receptors.
Evidence supports that activation of the cytokine pathway
could lead to inflammation of the carotid body associated
with an increased expression of inflammatory mediators and
an enhanced carotid chemoreceptor activity under sustained
hypoxic conditions. Indeed, the expression level of the
inflammatory mediator iNOS is significantly increased in the
carotid body of rats exposed to sustained hypoxia [15], which
could be functionally significant in being involved in the
endogenous production of NO in the carotid body under
hypoxic conditions [38]. Activation ofNF-𝜅Bpathwaymaybe
involved in the mechanistic aspects of the cytokine-induced
iNOS expression and the hypoxia-induced inflammatory
response of the carotid body [15, 29]. Furthermore, sustained
hypoxia induces the expression of chemokines (monocyte
chemoattractant protein- (MCP-) 1, chemokine receptor-
(CCR-) 2, macrophage inflammatory protein- (MIP-) 1𝛼,
and MIP-1𝛽) and adhesive molecule (intercellular adhesion
molecule- (ICAM-) 1) as well as infiltration of immune cells
in the carotid body of the rat [15, 29]. Anti-inflammatory
drug ibuprofen or dexamethasone attenuates the infiltra-
tion of macrophages and the expression of cytokines and
chemokines in the carotid body [29]. These findings give
support to the notion that the upregulated expression of
the cytokines and cytokine receptors significantly contributes
to the local inflammation of the carotid body in sustained
hypoxia.
Besides the upregulation of cytokines and cytokine recep-
tors, the inflammatory response of the carotid body to
sustained hypoxia could be mediated by endothelin-1. Liu
et al. [39] reported that pharmacological blockade of the
endothelin receptors with bosentan neutralizes the elevated
expression of proinflammatory cytokines, chemokines, and
macrophage infiltration in the carotid body. The expression
of endothelin-1 and endothelin receptors in the carotid body
is significantly upregulated in the sustained hypoxia [40, 41].
Thus, as aforementioned, inflammation of the carotid body is
likely to bemediated by locally regulated paracrine-autocrine
signals during sustained hypoxia. In addition, it is known
that plasma levels of cytokines are elevated under hypoxic
conditions.The circulating level of cytokines could also be an
important stimulus to induce the upregulation of the cytokine
signaling pathway in the carotid body, leading to the local
inflammation.
Moreover, inflammation of the carotid body is associated
with an increased expression of acid-sensitive iron chan-
nels (ASIC) in the chemoafferent neurons under sustained
hypoxia, hinting an altered chemoreceptor function under a
hypoxia-induced inflammatory condition resembling a con-
dition of hyperalgesia/hyperexcitability induced by chronic
pain/inflammation [42, 43]. Liu and colleagues [42] reported
that inflammatory cytokines significantly increase ASIC
expression in cultured petrosal ganglionic neurons, which
are the chemoafferent neurons of the carotid body. Also the
elevated ASIC expression in the animal exposed to sustained
hypoxia is blocked by concurrent treatment of a nonsteroidal
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anti-inflammatory drug ibuprofen. Importantly, the hypoxia-
induced enhanced carotid chemoreceptor activity recorded
from the carotid sinus nerve is significantly attenuated by
an ASIC antagonist A-317567 and also by ibuprofen. These
findings underscore an important role of ASIC in the carotid
body inflammation, which leads to an enhanced carotid
chemoreceptor activity under sustained hypoxic conditions.
Thus the inflammatory response of the carotid body to
sustained hypoxia may be an adaptive response of the carotid
chemoreceptor to facilitate the ventilatory acclimatization to
hypoxia at high altitude and also to adjust the ventilatory and
autonomic activities in response to hypoxia under disease
conditions.
In summary, evidence suggests that the increased expres-
sions of cytokines and cytokine receptors play a role in
the local inflammation of the carotid body induced by sus-
tained hypoxia. In effect, activation of the cytokine signaling
pathway increases the expression of inflammatory mediators
and chemokines, which mediates the local inflammatory
response of the carotid body. Thus, this upregulation could
increase the locally produced cytokines in addition to the
rise of circulating cytokines under hypoxic conditions, lead-
ing to activation of inflammatory signaling pathways. The
chemosensitive type-I glomus cell plays an important role
in this local inflammation because of the expression of
the cytokines and the cytokine receptors. The elevation of
cytokine levels could alter the response of the glomus cells
to hypoxia, which may be one of the cellular mechanisms
underlying the altered functions of the carotid body relevant
to the cardiopulmonary control under sustained hypoxic
conditions during physiological acclimatization to altitude
and also in diseases associated with chronic hypoxemia.
5. Pathogenic Role of the Chemoreflex in
Sleep Apnea
Recurrent apnea in patients suffering from sleep apnea leads
to intermittent hypoxia, which adversely impact the neu-
rocognitive and cardiovascular functions and increased risks
for stroke and cardiovascular disease [1, 2]. The physiolog-
ical compensatory response to arterial oxygen desaturation
in sleep apnea is significantly mediated by the chemore-
flex which triggers hyperventilation, parasympathoexcita-
tion contributing to bradycardia, and increased sympathetic
activities for the redistribution of blood flow in tissues and
organ [7]. However, repeated episodes of hypoxia induce aug-
mented activities of the carotid chemosensory activity and
ventilatory hypoxic responses [44, 45]. Mounting evidence
supports that the augmented activity of the carotid body
induced by intermittent hypoxia plays an important role in
the pathogenesis of sleep apnea [46, 47]. It has been proposed
that augmented activities of the chemoreflex significantly
contribute to a lowered activity of the central respiratory drive
leading to breathing instability in sleep apnea and also in
the pathophysiological impact of sleep apnea mediated by
increased sympathetic activities leading to hypertension [3].
Indeed, denervation of the carotid body could normalize the
elevated blood pressure induced by intermittent hypoxia in
animals [48, 49]. Altered chemosensitivity of the chemoreflex
has also been reported in patients with sleep apnea, which
significantly contributes to the overactivity of the sympathetic
activity mediated by the chemoreflex [50]. Recently, Marcus
and colleagues [51] reported that denervation of the carotid
body significantly attenuates disordered breathing patterns
and renal sympathetic activities in rabbits with cardiac pacing
simulating congestive heart failure. The mechanistic cause of
the augmented carotid chemoafferent activity is believed to
be multifactorial and it could be attributed to the oxidative
stress and inflammation induced by intermittent hypoxia [47,
52, 53]. In addition, maladaptive changes in the paracrine-
autocrine signaling in the carotid body have been proposed
to be responsible for the pathogenic response to intermittent
hypoxia [12].
Intermittent hypoxia induces elevated levels of reactive
oxygen species (ROS) and nitrogen reactive species leading
to oxidative stress, which causes cellular and tissue injuries in
organs. The oxidative stress induced by intermittent hypoxia
has been proposed as a significant factor contributing to
the pathogenesis of sleep apnea [54, 55]. Indeed, superoxide
dismutasewhich ismimetic attenuates the augmented carotid
chemoreceptor activity induced by intermittent hypoxia,
suggesting an involvement of ROS [44]. It has been proposed
that proinflammatory cytokines play a role in the increase
in cardiovascular morbidities as a pathophysiological con-
sequence of sleep apnea in patients [56]. Supporting this
idea, studies have demonstrated elevated levels of circulat-
ing proinflammatory cytokines including IL-6, TNF-𝛼, and
chemokines including MCP-1 in patients with obstructive
sleep apnea [57–59]. In addition, it has been shown that
proinflammatory cytokines and hypoxia increase the ROS
production, involving themitochondria andNADPHoxidase
[60, 61]. As aforementioned, the elevated proinflammatory
cytokines in the arterial blood increase the local expression
of proinflammatory cytokines and cytokine receptors in
the carotid body [15, 29]. Also, proinflammatory cytokines
significantly enhance the intracellular calcium response to
hypoxia in the chemosensitive glomus cells [15] and the
carotid chemoafferent activity [19, 29]. It has been proposed
that expressions of proinflammatory cytokines and cytokine
receptors in the carotid body play pathogenic roles in the
local inflammation and augmented activities of the carotid
body under chronic intermittent hypoxic condition which is
a hallmark feature of sleep apnea.
6. Intermittent Hypoxia Augments
Proinflammatory Cytokine Signaling and
Local Inflammation in the Carotid Body
Intermittent hypoxia induces a significant increase in the
mRNA and protein expression of proinflammatory cytokines
(IL-1𝛽, IL-6, and TNF-𝛼) and cytokine receptors (IL-1r1,
gp130, and TNF-r1) in the rat carotid body [18, 30, 52, 62].
The increased expression of proinflammatory cytokines and
receptors is localized to lobules of chemosensitive type-
I glomus cells and the proportional amount of the cells
expressing cytokines and cytokine receptors is significantly
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increased by a couple of days of intermittent hypoxia and
it remains at an elevated level in hypoxia up to a week
[18, 30, 52, 62]. Functional studies show that the effect of
exogenous IL-1𝛽, IL-6, and TNF𝛼 at 0.01–1 nM concentration
dependently increased the intracellular calcium response to
hypoxia by 10–40% in the glomus cell. The calcium response
is significantly augmented in cells obtained from rats exposed
to intermittent hypoxia [18]. These findings suggest that the
increase in local expression of proinflammatory cytokines
could increase the local release of cytokines under hypoxic
conditions. Also the upregulated expression of the cytokine
receptors augments the sensitivity of glomus cells to cytokines
under hypoxic conditions. Thus these local changes in the
cytokine signaling pathway could play a pathogenic role
in the local inflammation and augmented activities of the
carotid body induced by intermittent hypoxia.
7. Oxidative Stress and Inflammation in
the Carotid Body in Intermittent Hypoxia
Reports have shown that intermittent hypoxia induces oxida-
tive stress and inflammation in the carotid body. Hence, there
are significant elevated levels of markers of oxidative stress
including 8-isoprostane, malondialdehyde, and nitrotyrosine
in the serum and the carotid body of rats exposed to intermit-
tent hypoxia equivalent to a severe condition of sleep apnea
for days to weeks [52, 63]. In addition, there are significant
increases in the macrophage infiltration and the expression
of chemokines (MCP-1, CCR2, MIP-1𝛼, MIP-1𝛽, and ICAM-
1) in the carotid body [18, 52]. As mentioned, oxidative stress
could lead to cellular injuries and inflammation, which could
in turn induce the inflammatory response that could be an
important contributing factor in the altered function of the
carotid body in intermittent hypoxia. Indeed, the transcrip-
tional upregulation of the chemokines could increase the
invasion of immune cells in the carotid body participating in
the inflammatory process. Thus, the augmented expression
of chemokines induced by intermittent hypoxia plays a role
in the inflammation of carotid body, which could also be
mediated by oxidative stress induced by intermittent hypoxia.
Mechanistically, NADPH oxidase-dependent ROS gener-
ation has been shown to induce oxidative stress in local tissues
and increase expressions of proinflammatory cytokines and
chemokines via activation of NF𝜅B pathway [64, 65]. Indeed,
gene transcripts of NADPH oxidase subunits (gp91phox and
p22phox) are significantly increased in the carotid body in
intermittent hypoxia [18, 63]. Importantly, treatment of anti-
inflammatory drugs dexamethasone or ibuprofen signifi-
cantly attenuates levels of oxidative stress and gp91phox as
well as macrophage infiltration in the carotid body of the
rat in intermittent hypoxia [18]. Thus, the upregulated proin-
flammatory cytokine pathway could be initially activated by
tissue hypoxia [18, 29]. In turn, the inflammatory response
recruits infiltrated macrophages which also contribute to the
inflammatory cascade in the carotid body. More importantly,
increased levels in the ROS and oxidative stress induced by
intermittent hypoxia regulate the gene expression of inflam-
matory cytokines, chemokines, and adhesionmolecules [66].
As a result, these significantly contribute to the upregulated
cytokine pathways and local inflammation induced by inter-
mittent hypoxia in the carotid body.Moreover, proinflamma-
tory cytokines, including TNF𝛼 and IL-1𝛽, and HIF-1𝛼 also
cause the activation of NF𝜅b [67, 68]. The interplay of these
molecules and signaling pathways could lead to a positive
regulatory loop that may further enhance and exaggerate
the local inflammatory response in the carotid body. In fact,
administration of anti-inflammatory drug dexamethasone or
ibuprofen could attenuate the levels of macrophage infiltra-
tion and oxidative stress in the carotid body of rats exposed
to intermittent hypoxia [18]. Also, ibuprofen prevents the
elevated ventilatory response to hypoxia and arterial blood
pressure in intermittent hypoxia, although it fails to nor-
malize the augmented carotid chemosensory response to
hypoxia [52, 62]. Thus, the activation of proinflammatory
cytokine pathway could play mechanistic roles in mediating
the local inflammation and in contributing to the altered
function of the carotid body in intermittent hypoxia, leading
to the pathophysiology and pathophysiological consequences
of sleep apnea [12].
Besides, it has recently been shown that blockade of
angiotensin II AT
1
receptors with losartan significantly
attenuates the macrophage infiltration, oxidative stress, and
inflammation in the carotid body in intermittent hypoxia
[69]. There is an upregulation of the expression of a local
renin angiotensin system in the carotid body in intermittent
hypoxia, which significantly contributes to inflammation and
oxidative stress [69]. Marcus et al. [63] also reported that
losartan attenuates the expression of gp91phox and superoxide
production in the rat carotid body in intermittent hypoxia.
Also, activation of gp91phox mediates ROS production in
the carotid body via AT
1
receptor [70, 71]. These findings
support a pathogenic role of NADPH oxidase regulated
by AT
1
receptors in the local inflammation of the carotid
body. In effect, the upregulation of AT
1
receptors in the
carotid body could increase the NADPH oxidase-mediated
ROS production, which exaggerates the inflammation and
oxidative stress induced by intermittent hypoxia.
8. Perspectives of the Inflammation of
the Carotid Body-Clinical Implications in
Sleep Apnea
In premature infants, altered functions of the carotid body
have been known to be a key drive of the unstable breathing
leading to apnea of prematurity. The clinical conditions are
commonly associated with inflammation and infection. It
has been proposed that the inflammation of carotid body
could play a role in the changes in the chemosensitivity
of the carotid body, which adversely affects the stability of
breathing in the infant [72].Thus, targeting the inflammation
and the altered carotid body function may hint to a novel
therapeutic strategy for treating the sleep apnea and its
pathophysiological consequence. As shown in experimental
studies, anti-inflammatory drug prevents the inflammatory
response of the carotid body to intermittent hypoxia [18]
and also the elevated ventilatory response to hypoxia and
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Sleep apnea
Intermittent hypoxia
Oxidative stress
Carotid body inﬂammation
Cytokine signaling pathways
TNF receptors IL-1 receptors IL-6 receptors
Chemokines Inﬂammatory mediators
Macrophage infiltration NADPH oxidase
Augmented carotid chemoreceptor activity
Breathing instability and sympathetic overactivity
TNF𝛼 IL-1𝛽 IL-6
Figure 1: Schematic diagram shows the role of inflammation in the carotid body in the pathogenic cascade of sleep apnea. Arrows are the
direction of the pathogenic effects of oxidative stress and inflammation in the carotid body leading to augmented activities of the carotid
chemoreceptor and chemoreflex activity, significantly contributing to the pathophysiological consequence impacting on breathing instability
and autonomic imbalance.
arterial blood pressure in intermittent hypoxia, despite the
fact that the drug effect is less significant on the augmented
chemoreceptor activity [52, 62]. Nevertheless, these findings
suggest that local inflammation of the carotid body plays
a role in the altered chemoreflex induced by intermittent
hypoxia, although the inflammatory response may not be the
sole mechanism responsible for the augmented activity of the
chemoreceptor. Given that there are significant elevated levels
of the expression of proinflammatory cytokines TNF-𝛼 and
IL-6 and the expressions of endothelin-1 and angiotensin II in
the carotid body [18, 30, 52, 62, 69, 73], the augmented carotid
chemoreceptor response to hypoxia could bemediated by the
paracrine-autocrine signaling molecules involving upregu-
lated cytokine pathways, which contribute to the modulation
of the chemoreceptor activity in intermittent hypoxia [12].
In patients, anti-inflammatory medications could be use-
ful to alleviate the inflammation of the upper airway and
also to reduce the adenoidal size in children with obstructive
sleep apnea [74]. In clinical studies with small groups of adult
patients, administration of etanercept, a TNF-𝛼 antagonist,
significantly decreases the apnea-hypopnea index (AHI) and
IL-6 levels in the patient [75]. Also sleep apnea is less
common in patients with spondyloarthritis who received
TNF-inhibitor therapy [76]. In contrast, the AHI is worsened
after steroid treatment in the patients for 3 months [77]. Also
oral indomethacin administration increases AHI by about 2-
fold in healthy patients with mild obstructive sleep apnea,
which could be related to reductions in cerebral blood flow
and its response to CO
2
[78].Thus, clinical studies are limited
on the efficacy and effectiveness of the anti-inflammatory
drugs in the patient with sleep apnea. The effect of the
medication is highly dependent on the complex nature of
the etiology and pathophysiological cause of sleep apnea
in patients. As compared to the findings in experimental
animals, the inflammatory response is more related to the
impact of intermittent hypoxia equivalent to a severe level
of AHI. Future clinical studies in large patient group with
stratification of the inflammatory status and chemosensory
function may be useful to address the therapeutic potential
of targeting inflammation in the carotid body in sleep apnea.
9. Summary and Conclusion
The expression of proinflammatory cytokines and inflam-
matory mediators in the carotid body plays a pathogenic
role in sleep apnea. As shown in Figure 1, the cytokine
signaling pathway is part of the mechanistic cascade involved
in the augmented carotid chemoreceptor activity because
of the local upregulation of the proinflammatory cytokines,
cytokine receptors, and inflammatory mediators in the
carotid body. This in effect could significantly contribute
to the increased chemosensory activity and the afferent
activity of the chemoreflex, causing breathing instability in
sleep apnea. In addition, the increased chemoafferent activity
could lead to an increase in the sympathetic activity via
the chemoreflex. This in turn could significantly contribute
to the pathophysiological consequence of the sleep apnea,
namely, endothelial dysfunction leading to arterial hyperten-
sion and increased risks for cerebrovascular and cardiovas-
cular disease. In experimental animals, studies have shown
8 Mediators of Inflammation
that anti-inflammatory drugs could significantly attenuate
the inflammation of the carotid body and the augmented
carotid chemoreceptor activity induced by chronic intermit-
tent hypoxia. In parallel to the conventional treatment of
patients with continuous positive airway pressure for sleep
apnea, pharmacological intervention has been proposed to
alleviate the pathophysiological impact of sleep apnea aiming
to reduce the cardiovascular morbidities and mortalities in
the patients with sleep apnea. To this end, in addition to
the antihypertensive drugs, anti-inflammatory drugs may
also be implicative according to the recent advance in the
experimental study highlighting a pathogenic role of the
local inflammation of the carotid body. Also it is well
known that oxidative stress induced by intermittent hypoxia
exerts a systemic impact on multiple physiological systems
and organs, leading to significant levels of systemic and
chronic inflammation in patients with sleep apnea. Thus,
it is proposed that the anti-inflammatory drugs could have
significant effect not only on targeting the locally upregulated
cytokine pathways in the carotid body, but also on the
systemic inflammation in other systems and organs as well.
Future studies in this direction warrant further investigations
and clinical trials have yet to be conducted to confirm the
effectiveness of the treatment with anti-inflammatory drugs
in patients with sleep apnea.
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